Alliqua Biomedical (NASDAQ:ALQA) has been given a $5.00 target price by equities researchers at HC Wainwright in a research note issued to investors on Wednesday, January 3rd. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 134.74% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. ValuEngine upgraded Alliqua Biomedical from a “sell” rating to a “hold” rating in a research note on Friday, October 6th. Zacks Investment Research upgraded Alliqua Biomedical from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research note on Tuesday, September 12th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Alliqua Biomedical currently has a consensus rating of “Hold” and a consensus target price of $8.20.

How to Become a New Pot Stock Millionaire

Shares of Alliqua Biomedical (NASDAQ:ALQA) opened at $2.13 on Wednesday. Alliqua Biomedical has a 1 year low of $1.73 and a 1 year high of $8.48.

Alliqua Biomedical (NASDAQ:ALQA) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.03) by ($0.76). Alliqua Biomedical had a negative net margin of 155.55% and a negative return on equity of 110.42%. analysts forecast that Alliqua Biomedical will post -3.85 EPS for the current year.

WARNING: This report was first reported by Marea Informative and is owned by of Marea Informative. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at

Alliqua Biomedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with's FREE daily email newsletter.